ETF Midday Review | The battery sector leads the gains, with the energy storage battery ETF rising nearly 3%.

Gelonghui, September 3 | The three major indices of the A-share market experienced an overall decline. As of the midday break, the Shanghai Composite Index fell by 0.96%, the Shenzhen Component Index decreased by 0.63%, while the ChiNext Index remained flat. The North Exchange 50 Index dropped by 0.79%. The transaction volume in the Shanghai, Shenzhen, and Beijing markets reached 1.4722 trillion yuan, a decrease of 458.3 billion yuan compared to the previous day. Over 4,300 stocks in the entire market declined. In terms of sector performance, gaming, photolithography, film and television, semiconductors, and precious metals led the gains, while military equipment, securities, insurance, dairy, and pork sectors faced the largest declines. Regarding ETFs, the new energy battery sector saw significant growth, with the E Fund Energy Storage Battery ETF and the Energy Storage Battery ETF experiencing substantial increases.

Gelonghui FinanceSep 3 11:41

Midday ETF Review | The Innovative Drugs Sector continues to rise, with the Yinhua CSI Innovative Drugs Industry ETF premium increasing by 6%.

Gelonghui, July 30th | The three major A-share indices showed mixed performance. As of the midday session, the Shanghai Composite Index rose by 0.52%, the Shenzhen Component Index fell by 0.06%, and the GEM Index declined by 0.71%. The Beijing Stock Exchange 50 Index dropped by 0.54%. The total trading volume for the Shanghai, Shenzhen, and Beijing markets was 1.1022 trillion yuan, a decrease of 43.6 billion yuan from the previous day. Over 2,000 stocks in the two markets saw gains. In terms of sectors, the innovative drugs and film and cinema sectors performed well, while the battery, digital currency, and diversified financials sectors experienced adjustments. In the ETF sector, the Yinhua CSI Innovative Drugs Industry ETF continued to rise, with the Huabao Fund Hong Kong Stock Connect Innovative Drugs ETF, the Yongying Fund Hong Kong Stock Connect Healthcare ETF, and the Hwabao WP CSI Medical Service ETF increasing by 6%.

Gelonghui FinanceJul 30 11:43

Soaring again! Capital is frantically replenishing this track.

Biomedical stocks have collectively surged! Today, the market rotation accelerated in both A and Hong Kong stock markets, with sectors such as CNI Biomedicine Index and innovative medicine launching a strong offensive. By the market close, Sunshine Guojian Pharmaceutical in A-shares achieved a strong gain of 20CM on a locked limit, and REMEGEN, Yifang Biologics-U, Kexing Biopharm, Sanyuan Genetics, and WuHan Hvsen Biotechnology all rose over 10%. The performance of Hong Kong pharmaceutical companies was even more aggressive, with 3SBIO at one point increasing by over 40%, ultimately closing with a gain of 32.28%, driving a significant increase in many pharmaceutical stocks exceeding 10%. The Hang Seng Medical Index ETF (159557) also soared by 3.94% today, remarkably outperforming both markets.

Gelonghui FinanceMay 20 19:13

A news item triggered a decline in the Yinhua CSI Innovative Drugs Industry ETF and the Hong Kong Stock Connect Innovative Drugs ETF, while multiple Institutions remain Bullish on the Innovative Drugs Sector.

A piece of news reported that the Hong Kong stocks, A-shares, and Japan's Innovative Drugs Sector experienced a sudden drop. As of today's close, the Yinhua CSI Innovative Drugs Industry ETF, Hwabao WP CSI Medical Service ETF, Hong Kong Innovative Drugs 50 ETF, and Hong Kong Innovative Drugs ETF Fund fell by over 4%. In related news, Trump has new actions; he will sign an executive order on Monday to immediately reduce the prices of prescription drugs and pharmaceuticals in the USA by 30% to 80%. Trump stated on his social media regarding the issue of high drug prices in the USA: "For years, pharmaceutical companies have always claimed this is due to R&D costs, and for no reason, all these costs will be borne by the USA."

Gelonghui FinanceMay 12 16:12

The Medical sector has frequently issued Bullish policies, leading to a significant increase in the Hang Seng Yinhua CSI Innovative Drugs Industry ETF, Hang Seng Biotechnology ETF, Hang Seng Medical Index ETF, and Hong Kong Stock Connect Medical ETF.

Innovative Drugs and Medical stocks in Hong Kong surged, with INNOCARE, SIMCERE PHARMA, and ASCENTAGE-B rising over 12%; Lepu Biopharma-B, CMS, CSPC PHARMA, INNOVENT BIO, and Hutchmed (China) increased by more than 7%.

Gelonghui FinanceApr 22 10:59